Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Acotec Scientific Holdings's Revenue for the
six
months ended in Dec. 2025 was €35.58 Mil. Acotec Scientific Holdings's average Accounts Receivable for the
six
months ended in Dec. 2025 was €24.72 Mil.
Hence, Acotec Scientific Holdings's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.44.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Acotec Scientific Holdings Receivables Turnover Related Terms
Acotec Scientific Holdings Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7W3 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Acotec Scientific Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acotec Scientific Holdings Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acotec Scientific Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Acotec Scientific Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acotec Scientific Holdings (STU:7W3) has a Receivables Turnover of 1.44 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Acotec Scientific Holdings and its competitors. According to the industry distribution chart, Acotec Scientific Holdings ranks #716 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 88.3%.
Is Acotec Scientific Holdings' Receivables Turnover too high?
Acotec Scientific Holdings' current Receivables Turnover is 1.44. The Medical Devices & Instruments industry median Receivables Turnover is 5.58. Acotec Scientific Holdings' value of 1.44 is 74.2% below this industry median. Based on the distribution chart, Acotec Scientific Holdings ranks #716 out of 811 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Acotec Scientific Holdings has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Acotec Scientific Holdings' Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acotec Scientific Holdings ranks #716 out of 811 companies for Receivables Turnover. This places Acotec Scientific Holdings in the lower half of its industry. The industry median Receivables Turnover is 5.58. Acotec Scientific Holdings' value of 1.44 is 74.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.58, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acotec Scientific Holdings's current Receivables Turnover of 1.44 is 74.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Acotec Scientific Holdings and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acotec Scientific Holdings's current Receivables Turnover is 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acotec Scientific Holdings stock overvalued right now?
Acotec Scientific Holdings (STU:7W3) has a current Receivables Turnover of 1.44. The stock's GF Value™ is €1.58, compared to a current price of €0.68 — trading 57% below its estimated fair value. The current Receivables Turnover is 1.44 and 74.2% below the Medical Devices & Instruments industry median of 5.58. Acotec Scientific Holdings' overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Acotec Scientific Holdings (STU:7W3), the current Receivables Turnover is 1.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acotec Scientific Holdings (STU:7W3) Overvalued in 2026?
Based on GuruFocus' analysis, Acotec Scientific Holdings stock appears to be undervalued.
The current stock price of €0.68 is trading 57% below its estimated GF Value™ of €1.58.
Key valuation signals for STU:7W3:
Receivables Turnover: 1.44
GF Value™: €1.58 vs. price of €0.68 (57% below fair value)
Industry Position: 74.2% below the Medical Devices & Instruments median (#716 of 811)
No single metric tells the full story. See the STU:7W3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acotec Scientific Holdings Ltd is a medical technology company, focusing on the research and development, and application of technology platforms in the field of vascular interventional treatment. Its product portfolio comprises Semi-compliant PTCA balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), Coronary CTO Antegrade Micro-Catheter (Vericor-14), Coronary High-Pressure Balloon (YIYAN), Coronary CTO Retrograde Micro-Catheter (Vericor-RS), Cardiac Valve Balloon Dilation Catheter (RunFlow), etc., and also has various other products in its development pipeline. Geographically, the company generates a majority of its revenue from Mainland China, and the rest from other regions. The firm generates the majority of its revenue from sales to Domestic distributors.
76GF Score
Get the complete analysis for STU:7W3
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7W3 has been successfully added to your 
